key: cord-1029187-5tfs6l0v authors: Subramani, Bhavani; Sathiyarajeswaran, P. title: Current update on herbal sources of antithrombotic activity—a comprehensive review date: 2022-03-07 journal: Egypt J Intern Med DOI: 10.1186/s43162-021-00090-9 sha: ccd5c70a1b8e2216332c34153b503cd4639490c9 doc_id: 1029187 cord_uid: 5tfs6l0v BACKGROUND: Herbs are commonly used to treat cardiovascular diseases in various traditional medicine. On the other hand, herb-drug interactions are most commonly encountered with conventional antiplatelet and anticoagulant drug prescriptions. This review presents a compilation of plants investigated for antiplatelet and anticoagulation recently and enumerates their possible lead compounds responsible for its action for paving further drug discovery and knowledge update. MAIN BODY OF THE ABSTRACT: Information about the herbs was withdrawn from the PubMed database of the previous 5 years. We also hand-searched the bibliography of relevant articles for the acquisition of additional information. About 72 herbal sources were identified with the effect of antiplatelet activity, antithrombotic activity, and anticoagulant activity. Bioactive compounds and various secondary metabolites responsible for it, such as alkaloids, saponins, flavonoids, coumarins, polyphenols, furan derivatives, iridoid glycosides, sesquiterpenes, aporphine compounds, were reported. CONCLUSION: Newer pharmacological moieties are needed to prevent or reduce the adverse effects of current anti-thrombotic agents and to improve the safety of patients and cost-effectiveness. Cardiovascular disease (CVD) due to thrombosis comprises coronary artery disease (CAD), stroke, hypertension, peripheral arterial disease (PAD), venousthrombo-embolic disease (VTE) [1] . As per the National Health and Nutrition Examination Survey (NHANES) 2013-2016, the prevalence of Coronary heart disease (CHD) in the USA was estimated as 18.2 million in > 20 years of age with more risk among males than females, whereas the prevalence of ischaemic stroke was 67.6 million and that of hemorrhagic stroke was 15.3 million [2]. CVD and stroke accounted for 14% of the total expenditure in 2014-2015, more than any diagnostic group results in immense health and economic burden in the USA globally. The AHA's 2020 Impact Goals are to improve the cardiovascular health of all Americans by 20% while reducing deaths attributable to CVD and stroke by 20% [1] . Currently, witnessing an unprecedented pandemic, the coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS Co-V-2), associated with a significant risk of thromboembolic complications due to hypercoagulability state of blood which is called as Covid-19 associated coagulopathy (CAC) [3] . Though prophylaxis anti-coagulants were administered, the incidence of VTE complications was reported in twothirds of ICU cases [4] and developed life-threatening thrombotic complications followed by Acute respiratory distress syndrome (ARDS) [5] . Venous thromboembolism Page 2 of 12 Subramani and Sathiyarajeswaran The Egyptian Journal of Internal Medicine (2022) 34:26 (VTE), a major cardiovascular complication, was observed in about more than 20% of critically ill COVID-19 cases, particularly among critically ill viral pneumonia patients [4] . Histologically, significant thrombosis in small blood vessels and micro-vasculature of pulmonary and extra-pulmonary organs have been confirmed [6] , widespread prevalence of deep vein thrombosis and pulmonary embolism, as well as microthrombi in the small pulmonary vessels in autopsy findings [7] . Several hypotheses on the mechanism of thrombosis in Covid-19 have been proposed and remain unclear. Thrombosis can be classified as arterial thrombosis and venous thrombosis although overlaps may be present. In general, pharmacologically two classes of drugs are used to prevent blood clots such as antiplatelets and anticoagulants [8] . Antiplatelets act by inhibition of platelet adhesion and activation and aggregation of thrombosis [9] . Thrombosis refers to the formation of platelet or fibrin aggregation in the lumen of the blood vessels or heart [10] . Anticoagulants prevent blood clot formation by interfering with proteins responsible for blood clotting or clotting factors [8] . Hypercoagulability is the state of increased tendency to the formation of thrombosis also triggering intracellular signalling for inflammation [10] . The use of antithrombotic medications remains the mainstay of treatment in cardiovascular and cerebrovascular disorders. Aspirin and clopidogrel were the commonly administered antiplatelet drugs to reduce recurrent ischaemic events in CAD and ischaemic stroke. Oral anticoagulants are prescribed for primary prevention and secondary prevention of venous thromboembolic disease [11] and as the best option in the prevention of stroke due to cardio-embolism in atrial fibrillation [12] . Aspirin is prone to cause gastrointestinal side effects, hypersensitivity, hypo-responsiveness in some, and bleeding episodes [13] . Low-dose aspirin is commonly used as primary and secondary prevention of cardiovascular disease, which is associated with the risk of upper and lower gastro-intestinal tract lesions, particularly in the upper gastro-intestinal tract which may cause asymptomatic lesions to peptic ulcer bleeding and/or even death Li et al. [14] . Until recently, the vitamin K antagonists were the only oral anticoagulant agents available and warfarin remains the most commonly prescribed oral anticoagulation worldwide [15] . Warfarin has significant variability in dose-response across individuals and a narrow therapeutic window and intensive therapeutic monitoring are essential. When combined with low-dose aspirin, NSAIDs, or clopidogrel, warfarin acts cumulatively and the risk of bleeding is significantly increased [16] The risk of major bleeding associated with oral anti-coagulants ranges from 3.26 to 7.2% annually [11] . Both oral anticoagulation and antiplatelet therapies are essential in 20-30% of patients with co-existing atrial fibrillation (AF) and CAD, together posing a major risk of thrombotic complications [17] . Currently, in the management of patients with IHD and AF, include triple therapy TT (an anticoagulant plus 2antiplatelet drugs) and two types of dual therapy, DAPT (2 antiplatelet drugs) or DT (an anticoagulant plus a single antiplatelet drug) [18] . Herbs play an indispensable role in natural product discovery to meet the growing healthcare needs. Researchers screen herbal sources through reverse pharmacology and observational therapeutics to find novel compounds and harness the potential for future drug discovery. According to WHO (World Health Organization), about 80% of the World's population depends on medicinal plants or herbs to fulfill their medicinal needs. Herbal medicines are a maximum part of complementary and alternative medicine and preferred treatment of people for various reasons such as ethnicity of use, family traditions, and past good experiences [19] . In this review, we have covered 72 herbs, their extracts, their secondary metabolites, and their pharmacological activities studied in both in vivo, ex vivo, and in vitro investigations. Acknowledging the growing significance of traditional medicine and usage, the WHO global report on traditional and complementary medicine 2019 states about the steps taken to promote the safety, quality, and effectiveness of traditional medicine by developing the WHO Traditional Medicine Strategy 2014-2023, in line with WHO Traditional Medicine Strategy (2002) (2003) (2004) (2005) . Healthcare professionals need to be aware of and monitor possible risks of concomitant medications of herbs with conventional medicine prescriptions if any [20] . We conducted a PubMed search for the in-vitro and in vivo studies published between 2016 and 2020 till December using multiple combinations of keywords, including the following: "anti-thrombotic activity", "antiplatelet activity", "anti-coagulant", "antiplatelet aggregation", "anti-hyper-viscosemia", "anti-aggregant", "platelet agglutination inhibitor", "platelet aggregation inhibitor", "platelet targeted pharmacologic agents", "antiplatelet adhesion", "medicinal plants", and "herbal sources". We found 296 publications that were reviewed by two authors. The retrieved articles were examined mechanisms had been postulated such as inhibition of ADP-induced platelet aggregation, inhibition of the arachidonic acid pathway, thereby inhibiting biosynthesis of thromboxane A2; plants containing lignans, xanthones, sesquiterpenes, flavonoids affect coagulation by inhibiting platelet-activating factor (PAF), or PAF receptor antagonists, inhibiting the factor X on the coagulation cascade. Plants containing the coumarin class of compounds antagonise vitamin K and Plant-derived compounds such as alkaloids, anthraquinones, coumarins, flavonoids, xanthones, Lignans, saponins, stilbenes, etc. were found to affect platelet aggregation activity Werner Cordier et al. [91] . Inhibition of platelet adhesion or chemical mediators for activation of platelet function is the common potential of herbs for its antiplatelet activity. Various prevent coagulation. Few naturally occurring compounds contain fibrinolytics which may activate plasminogen and affect coagulation. Phytochemicals that inhibit the CYP3A4, CYP2C9, and CYP1A2 metabolism were potent to affect coagulation Leite et al. [92] . Herbs identified in this review were listed with possible mechanisms of action responsible for their pharmacological activity in Table 2 . Among older adults, concomitant herbal medicine use along with prescription drugs had been reported as 5.3 Table 3 Common therapeutic indication of herbs Angelica sinensis (Oliv.) Diels Promoting circulation Lu et al. [97] Andrographis paniculata (Burm.f.) Nees Myocardial ischaemia, fever, respiratory infections Zhang et al. [6] Apium graveolens Linn Hepatic and spleen disorders, brain disorders, sleep disturbances Al-Asmari et al. [98] Allium sativum L. Hypercholesterolaemia Izzo et al. [96] Aesculus hippocastanum L. Anti-inflammatory, venotonic Sparg et al. [29] Carthamus tinctorius L. Chest pain, traumatic injuries Lim et al. [99] Curcuma longa L. Chest pain, amenorrhoea Lim et al. [99] Centella asiatica L. (Urb). Improving memory Satake et al. [46] Ginkgo biloba L. to 88.3% in a systematic review as potential cause of herbal-drug interaction Agbabiaka et al. [93] . Herbdrug interactions (HDI) may be either due to pharmacokinetic or pharmacodynamic interactions which affects the safety and efficacy of the treatment. Pharmacokinetic interactions affect the absorption, distribution, metabolism, and excretion of drugs which in turn results in a change in drug concentration in body fluids Lee et al. [94] . Various mechanism has been postulated for the altered drug concentration such as induction or inhibition of hepatic and intestinal drug-metabolizing enzymes such as cytochrome P450, UDP-glucorynyl transferase, and carrier proteins such as P-glycoprotein was suggested Kahrman et al. [95] . While pharmacodynamic interactions are related to the pharmacological activity of the interacting agents which may be synergistic or additive resulting in toxicities or antagonistic causing treatment failure Izzo [96] . Few frequently reported herbs, with its commonly used therapeutic indications (Table 3) , and drug interactions with conventional anti-thrombotic medicines were enumerated with increased risk of bleeding as per current evidence (Tables 4, 5, and 6) and types of herb-drug interaction of few herbs are summarised (Table 7) . Salvia miltiorrhiza, Angelica sinensis (Oliv.) Diels and Zingiber officinale Roscoe were identified to cause major interactions with anticoagulant or antiplatelet drugs may lead to life-threatening complications or serious adverse events (Tsai et al. [110] ). In this review, extensive search has been done on herbal sources investigated for anti-thrombotic activity recently were highlighted. Adverse haemorrhagic complications Table 4 List of herb-aspirin interaction causing increased risk of bleeding Angelica sinensis (Oliv.) Diels Xiao et al. [103] Carthamus tinctorius L. Lim et al. [99] Curcuma longa L. Hu and Wang [104] Ginkgo biloba L. Hu and Wang [104] Panax ginseng Meyer Hu and Wang [104] Salvia miltiorrhiza Hu and Wang [104] ; Xiao et al. [103] No funding. Data sharing not applicable to this article as no data sets were generated or analyzed during the current study. Ethics approval and consent to participate Not applicable. Not applicable. Authors have no conflict of interest. Zingiber officinale Roscoe (B) PAF inhibitor Leite et al. [92] Singhania G (2020) Current overview on hypercoagulability in COVID-19 Incidence of thrombotic complications in critically ill ICU patients with COVID-19 High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease E040. Available from Autopsy findings in COVID-19-related deaths: a literature review Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome Composition of coronary thrombus in acute myocardial infarction Recent advances in haemostasis and thrombosis The perils of combination antithrombotic therapy and potential resolutions General mechanisms of coagulation and targets of anticoagulants (section I): position paper of the ESC Working Group on Thrombosis -Task Force on anticoagulants in heart disease Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome Effects of aspirin on the gastrointestinal tract: Pros vs. cons American College of Chest Physicians evidence-based clinical practice guidelines Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands Guidelines for the management of atrial fibrillation Efficacy and safety of triple versus dual antithrombotic therapy in atrial fibrillation and ischemic heart disease: a systematic review and meta-analysis Why people use herbal medicine: insights from a focus-group study in Germany Uncertain associations of major bleeding and concurrent use of antiplatelet agents and Chinese medications: a nested case-crossover study Xanthoangelols isolated from Angelica keiskei inhibit inflammatory-induced plasminogen activator inhibitor 1 (PAI-1) production Z-ligustilide extracted from Radix angelica sinensis decreased platelet aggregation induced by ADP ex vivo and arterio-venous shunt thrombosis in vivo in rats Traditional uses, chemical constituents, biological properties, clinical settings, and toxicities of Abelmoschus manihot L.: a comprehensive review Inhibitoryeffect of Andrographis paniculata extract and its active diterpenoids onplatelet aggregation Antiplatelet and antithrombotic activities of timosaponin B-II, an extract of Anemarrhena asphodeloides Antiplatelet and antithrombotic activity of L-3-n-butylphthalide in rats The genus Achyranthes: a review on traditional uses, phytochemistry, and pharmacological activities Antiplatelet constituents of garlic and onion Biological activities and distribution of plant saponins vitro antiatherothrombotic effects of extracts from Berberis Vulgaris L., Teucrium Polium L., and Orthosiphon Stamineus Benth. Evid Based Complement Altern Med Antiplatelet, antithrombotic, and fibrinolytic activities of Campomanesia xanthocarpa. Evid Based Complement Altern Med Antiplatelet effects of Cyperus rotundus and its component (+)-nootkatone Hydro-methanolic extract of Cornus mas L. and blood glucose, lipid profile and hematological parameters of male rats Antiplatelet and vasorelaxing actions of aporphinoids from Cassytha filiformis Inhibitory effect of compounds from Zingiberaceae species on human platelet aggregation Chrysanthemum indicum L.: a comprehensive review of its botany, phytochemistry and pharmacology Platelet anti-aggregation activities of compounds from Cinnamomum cassia Effects of unripe Citrus hassaku fruits extract and its flavanone glycosides on blood fluidity Study progress of berberine for treating cardiovascular disease Anti-thrombotic effect of Carthamus tinctorius linn extracts in rats Brazilin isolated from Caesalpinia sappan L. acts as a novel collagen receptor agonist in human platelets Anticoagulant activities of curcumin and its derivative Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets Antiplatelet, anticoagulant, and profibrinolytic activities of cudratricusxanthone A Chemical constituents of Callicarpa nudiflora and their anti-platelet aggregation activity The antithrombotic active constituents from Centella asiatica Bioactive sesquiterpenes isolated from the essential oil of Dalbergia odorifera T Dioscorea zingiberensis C. H. Wright: an overview on its traditional use, phytochemistry, pharmacology, clinical applications, quality control, and toxicity Anti-thrombotic activity and chemical characterization of steroidal saponins from Dioscorea zingiberensis The anticoagulant fraction from the leaves of Diospyros Kaki L. has an antithrombotic activity Protective effect of Euphorbia neriifolia extract on experimentally induced thrombosis in murine model Antithrombotic effect of rutaecarpine, an alkaloid isolated from Evodia rutaecarpa, on platelet plug formation in in vivo experiments Anticoagulant and anti-platelet activity of polyphenolic-polysaccharide preparation isolated from the medicinal plant Erigeron canadensis L Advances in the studies of Ginkgo biloba leaves extract on aging-related diseases Antithrombotic phenolic compounds from Glycyrrhiza uralensis Thrombin receptor (PAR-1) antagonists as novel antithrombotic agents Alkaloids from Houttuynia cordata and their antiplatelet aggregation activities Anti-platelet aggregation alkaloids and lignans from Hernandia nymphaeifolia Aporphine alkaloids and cytotoxic lignans from the roots of Illigera luzonensis Antithrombotic effect of chikusetsusaponin IVa isolated from Ilex paraguariensis (Maté) Leonurus sibiricus L. (honeyweed): a review of its phytochemistry and pharmacology. Asian Pac Novel antiplatelet activity of protocatechuic acid through the inhibition of high shear stress-induced platelet aggregation Effects of L. F04, the active fraction of lycopus lucidus, on erythrocytes rheological property The saponin D39 blocks dissociation of non-muscular myosin heavy chain IIA from TNF receptor 2, suppressing tissue factor expression and venous thrombosis Antiplatelet and antithrombotic effects of the extract of Lindera obtusiloba leaves Quinoline alkaloids and other constituents of Melicope semecarpifolia with antiplatelet aggregation activity A review of the phytochemistry and pharmacological activities of Magnoliae officinalis cortex Assessment of anti-coagulant activity of Nelumbo nucifera fruit -PubMed Comparative effects of Artemisia dracunculus, Satureja hortensis and Origanum majorana on inhibition of blood platelet adhesion, aggregation and secretion Osmanthus fragrans seeds, a source of secoiridoid glucosides and its antioxidizing and novel platelet-aggregation inhibiting function Antiplatelet effects of acidamides isolated from the fruits of Piper longum L Platelet anti-aggregatory and blood anti-coagulant effects of compounds isolated from Paeonia lactiflora and Paeonia suffruticosa -PubMed Antithrombotic activity and saponin composition of the roots of Panax bipinnatifidus Seem. growing in Vietnam Antiplatelet activity of N-methoxycarbonyl aporphines from Rollinia mucosa Inhibition of platelet activating factor by ajmaline in platelets: in vitro and in vivo studies Cytotoxic and antiplatelet aggregation principles of Ruta Graveolens Antiplatelet effects of bioactive compounds isolated from the bark of Rhus verniciflua Stokes Anti-platelet stilbenes from aerial parts of Rheum palaestinum A novel bis-furan derivative, two new natural furan derivatives from Rehmannia glutinosa and their bioactivity Antiplatelet aggregation activity of diterpene alkaloids from Spiraea japonica Antiplatelet, anticoagulant, and profibrinolytic activities of baicalin Antiplatelet effects of Spatholobus suberectus via inhibition of the glycoprotein IIb/ IIIa receptor Anti-platelet effects of flavonoids and flavonoid-glycosides from Sophora japonica Comparing coagulation activity of Selaginella tamariscina before and after stirfrying process and determining the possible active constituents based on compositional variation 16-Dihydrotanshinone I, a major component from Salvia miltiorrhiza Bunge (Dansham), inhibits rabbit platelet aggregation by suppressing intracellular calcium mobilization Sapinmusaponins F-J, bioactive tirucallane-type saponins from the galls of Sapindus mukorossi The effect of silymarin flavonolignans and their sulfated conjugates on platelet aggregation and blood vessels ex vivo A new dicoumarin and anticoagulant activity from Viola yedoensis Makino Antitumor and antiplatelet activity of alkaloids from veratrum dahuricum Anti-platelet aggregation and vasorelaxing effects of the constituents of the rhizomes of zingiber officinale Herbal remedies affecting coagulation: A review Review on mechanisms and interactions in concomitant use of herbs and warfarin therapy Concurrent Use of Prescription Drugs and Herbal Medicinal Products in Older Adults: A Systematic Review Antithrombotic properties of JJ1, a potent and novel thrombin inhibitor The Clinical importance of herb-drug interactions and toxicological risks of plants and herbal products Interactions between herbs and conventional drugs: overview of the clinical data Knowledge Mapping of Angelica sinensis (Oliv.) Diels (Danggui) Research: A Scientometric Study Traditional Chinese medicine: herb-drug interactions with aspirin Review of Antiplatelet Activity of Traditional Medicinal Herbs on Integrative Medicine Studies. Evidence-based complementary and alternative medicine. eCAM 7125162 Clinically Relevant Herb-Micronutrient Interactions: When Botanicals, Minerals, and Vitamins Collide Medicinal Herbals with Antiplatelet Properties Benefit in Coronary Atherothrombotic Diseases. Thrombosis 5952910 Impact of the Chinese herbal medicines on dual antiplatelet therapy with clopidogrel and aspirin: Pharmacokinetics and pharmacodynamics outcomes and related mechanisms in rats Interactions between clopidogrel and traditional Chinese medicine Updates on the clinical evidenced herbwarfarin interactions. Evidence-based complementary and alternative medicine: eCAM 957362 Anti-coagulant activity of plants: mini review Mechanisms and interactions in concomitant use of herbs and war far in therapy: An updated review Herb-drug interaction studies of herbs used in treatment of cardiovascular disorders-A narrative review of preclinical and clinical studies Pharmacokinetic Interactions between Cardiovascular Medicines and Plant Products A review of potential harmful interactions between anticoagulant/antiplatelet agents and Chinese herbal medicines Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations